Is It Safe to Take a GLP-1 Medication While Breastfeeding?
FAQ-000048
Direct Answer
Official guidance from manufacturers and most clinical specialists recommends avoiding GLP-1 medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), while breastfeeding, since effects on a nursing infant haven't been established through large safety trials. That said, a 2024 published study measuring actual breast milk samples found semaglutide levels were largely undetectable, early evidence of low transfer, but importantly, not the same thing as proven safety. This is a genuine area of ongoing research, not a fully settled question, and it's worth understanding both sides rather than only the cautious label or only the reassuring data point.
Why the Official Guidance Is Cautious
The FDA states that effects on a breastfed infant from GLP-1 exposure are unknown, and Wegovy and Ozempic's own prescribing information recommends stopping the medication at least two months before planning pregnancy to fully clear it from the body. This caution reflects an absence of large-scale safety data, not a specific finding of harm, but absence of proof of safety is treated seriously in this specific population, since infants can't consent to exposure and are more vulnerable to medication effects generally.
What the Emerging Research Actually Shows
A 2024 study published in the journal Nutrients measured semaglutide levels directly in human milk samples from women taking the medication, using milk from the InfantRisk Center's biorepository. The findings suggested notably low transfer into breast milk. Separately, GLP-1 medications are large peptide molecules that are broken down by stomach acid and intestinal enzymes rather than absorbed intact, meaning even if a very small amount reaches breast milk, it's theorized that an infant's digestive system would likely break it down before meaningful absorption could occur. This is a plausible, but still not fully proven, mechanism.
This Is a Real, Growing Question for a Lot of People
The InfantRisk Center at Texas Tech University, a dedicated medication-and-lactation safety resource, reported more than a 500% increase in inquiries specifically about GLP-1 medications and breastfeeding between 2021 and 2024. A research letter published in JAMA in late 2025 confirmed GLP-1 medications are increasingly being used by women in the postpartum period specifically. You are not alone in asking this question, and it's a legitimate, common one, not a fringe concern.
What This Means Practically
Most physicians currently approach this conservatively, either recommending delaying GLP-1 therapy until breastfeeding concludes, or, for mothers with compelling medical reasons like existing type 2 diabetes or severe obesity with real health complications, involving shared decision-making between the prescribing provider, an obstetrician, and a lactation specialist. This isn't a decision to make from general information alone, given how genuinely unsettled the actual safety data still is.
References
- Diab H, et al. Subcutaneous Semaglutide during Breastfeeding, Infant Safety Regarding Drug Transfer into Human Milk. Nutrients, 2024
- TODAY: Is Semaglutide Safe While Breastfeeding? Doctors Explain (citing InfantRisk Center data)
- Ozempic and Wegovy Prescribing Information (FDA)
Related Resources
Related Articles
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and does not constitute medical advice. If you are breastfeeding and considering a GLP-1 medication, discuss your specific situation directly with your prescriber, your baby's pediatrician, and a lactation specialist before making any decision.
glp-1-and-breastfeeding